A Positron Emission Tomography (PET) Study to Compare the [18F]P16-129 and [18F]Florbetapir for Investigations of Amyloid β Pathology in Subjects With Alzheimer's Disease and Investigate the Biokinetics, Radiation Dosimetry, and Safety of [18F]P16-129 in Healthy Volunteers
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Fluorine 18 P16 129 (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Five Eleven Pharma
Most Recent Events
- 16 Jul 2021 Status changed from active, no longer recruiting to completed.
- 27 May 2020 Planned End Date changed from 1 Apr 2020 to 18 Jun 2020.
- 16 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Apr 2020.